Artículos de revistas
The Beta-3 Adrenoceptor Agonist, Mirabegron Relaxes Isolated Prostate From Human And Rabbit: New Therapeutic Indication?
Registro en:
Prostate. John Wiley And Sons Inc., v. 75, n. 4, p. 440 - 447, 2015.
2704137
10.1002/pros.22930
2-s2.0-84920828904
Autor
Calmasini F.B.
Candido T.Z.
Alexandre E.C.
D'Ancona C.A.
Silva D.
De Oliveira M.A.
De Nucci G.
Antunes E.
Monica F.Z.
Institución
Resumen
BACKGROUND. Alpha1 (α1)-blockers, 5-alpha reductase and phosphodiesterase type-5 inhibitors are pharmacological classes currently available for benign prostatic hyperplasia (BPH) treatment. Mirabegron, a beta-3 adrenoceptor (β3-AR) agonist has been approved for the therapy of overactive bladder and may constitute a new therapeutic option for BPH treatment. This study is aimed to evaluate the in vitro effects of mirabegron in human and rabbit prostatic smooth muscle. METHODS. In rabbit prostate, electrical field stimulation (EFS)-induced contraction and concentration-response curve (CRC) to mirabegron in phenylephrine pre-contracted tissues were carried out. The potency (pEC50) and maximal response (Emax) values were determined. In human prostate, CRC to phenylephrine was carried out in the absence and presence of mirabegron. Immunohistochemistry analysis for β3-AR was also carried out. RESULTS. In human prostate, immunohistochemistry analysis revealed the presence of β3-AR on the transition zone and mirabegron reduced by 42% the phenylephrine-induced contractions. In rabbit prostate, mirabegron produced concentration-dependent relaxations (pEC50: 6.01 ± 0.12; Emax: 106 ± 3%), which were fully resistant to the blockade of β1-AR and β2-AR. The β3-AR blocker L748,337 caused a six-fold rightward shift in mirabegron-induced relaxations. Mirabegron (10 μM) reduced by 63% the EFS-induced contractions. Inhibitors of nitric oxide (L-NAME) and of soluble guanylate cyclase (ODQ) along with a cocktail of K+ channel blockers (apamin, charybdotoxin, glibenclamide, tetraethylammonium) all failed to significantly affect the mirabegron-induced rabbit relaxations. CONCLUSION. Mirabegron relaxes prostatic smooth muscle, providing an experimental support for the clinical investigation of its combination with an α1-blockers or PDE5 inhibitors in the treatment of BPH. 75 4 440 447 Chapple, C.R., Wein, A.J., Abrams, P., Dmochowski, R.R., Giuliano, F., Kaplan, S.A., McVary, K.T., Roehrborn, C.G., Lower urinary tract symptoms revisited: A broader clinical perspective (2008) Eur Urol, 54, pp. 563-569 Nicolosi, A., Moreira, E.D., Jr., Shirai, M., Mohd, B., Tambi, M.I., Glasser, D.B., Epidemiology of erectile dysfunction in four countries: Cross-national study of the prevalence and correlates of erectile dysfunction (2013) Urology, 61, pp. 201-206 McVary, K., Lower urinary tract symptoms and sexual dysfunction: Epidemiology and pathophysiology (2006) BJU Int, 97, pp. 23-28 Parsons, J.K., Schenk, J.M., Arnold, K.B., Messer, K., Till, C., Thompson, I.M., Kristal, A.R., Urologic Diseases in America Project, Finasteride reduces the risk of incident clinical benign prostatic hyperplasia (2012) Eur Urol, 62, pp. 234-241 Oelke, M., Giuliano, F., Mirone, V., Xu, L., Cox, D., Viktrup, L., Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial (2012) Eur Urol, 61, pp. 917-925 Chapple, C.R., Cardozo, L., Nitti, V.W., Siddiqui, E., Michel, M.C., Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability (2014) Neurourol Urodyn, 33, pp. 17-30 Haynes, J.M., Hill, S.J., Beta-adrenoceptor-mediated inhibition of alpha-1-adrenoceptor-mediated and field stimulation-induced contractile responses in the prostate of the guinea pig (1997) Br J Pharmacol, 122, pp. 1067-1074 Kalodimos, P.J., Ventura, S., Beta-2-adrenoceptor-mediated inhibition of field stimulation induced contractile responses of the smooth muscle of the rat prostate gland (2001) Eur J Pharmacol, 431, pp. 81-89 Haynes, J.M., Beta(2) and beta(3)-adrenoceptor inhibition of alpha(1)-adrenoceptor-stimulated Ca(2 +) elevation in human cultured prostatic stromal cells (2007) Eur J Pharmacol, 570, pp. 18-26 Hofmann, F., Feil, R., Kleppisch, T., Schlossmann, J., Function of cGMP-dependent protein kinases as revealed by gene deletion (2006) Physiol Rev, 86, pp. 1-23 Belge, C., Hammond, J., Dubois-Deruy, E., Manoury, B., Hamelet, J., Beauloye, C., Markl, A., Balligand, J.L., Enhanced expression of beta3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase (2014) Circulation, 129, pp. 451-462 Lepor, H., Kazzazi, A., Djavan, B., Alpha-Blockers for benign prostatic hyperplasia: The new era (2012) Curr Opin Urol, 22, pp. 7-15 Nomiya, M., Yamaguchi, O., A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders (2003) J Urol, 170, pp. 649-653 Matsumoto, R., Otsuka, A., Suzuki, T., Shinbo, H., Mizuno, T., Kurita, Y., Mugiya, S., Ozono, S., Expression and functional role of β3-adrenoceptors in the human ureter (2013) Int J Urol, 20, pp. 1007-1014 Cirino, G., Sorrentino, R., Bianca, D.V., Popolo, R., Palmieri, A., Imbimbo, C., Fusco, F., Mirone, V., Involvement of beta-3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function (2003) Proc Natl Acad Sci USA, 100, pp. 5531-5536 Berkowitz, D.E., Nardone, N.A., Smiley, R.M., Price, D.T., Kreutter, D.K., Fremeau, R.T., Schwinn, D.A., Distribution of beta-3-adrenoceptor mRNA in human tissues (1995) Eur J Pharmacol, 289, pp. 223-228 Soeder, K.J., Snedden, S.K., Cao, W., Rocca, D., Daniel, G.J., Luttrell, K.W., Collins, L.M., The beta-3-adrenergic receptor activates mitogen-activated protein kinase in adipocytes through a Gi-dependent mechanism (1999) J Biol Chem, 274, pp. 12017-12022 Hristov, K.L., Cui, X., Brown, S.M., Liu, L., Kellett, W.F., Petkov, G.V., Stimulation of beta-3-adrenoceptors relaxes rat urinary bladder smooth muscle via activation of the large-conductance Ca2 +-activated K+ channels (2008) Am J Physiol Cell Physiol, 295, pp. 1344-1353 Takasu, T., Ukai, M., Sato, S., Matsui, T., Nagase, I., Maruyama, T., Sasamata, M., Yamaguchi, O., Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl) amino]ethyl} acetanilide (YM178), a novel selective beta-3-adrenoceptor agonist, on bladder function (2007) J Pharmacol Exp Ther, 321, pp. 642-647 Hatanaka, T., Ukai, M., Watanabe, M., Someya, A., Ohtake, A., Suzuki, M., Ueshima, K., Sasamata, M., In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats (2013) Naunyn Schmiedebergs Arch Pharmacol, 386, pp. 247-253 Haynes, J.M., Cook, A.L., Protein kinase G-induced activation of K(ATP) channels reduces contractility of human prostate tissue (2006) Prostate, 66, pp. 377-385 Kohler, R., Kaistha, B.P., Wulff, H., Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease (2010) Expert Opin Ther Targets, 14, pp. 143-155 Rozec, B., Erfanian, M., Laurent, K., Trochu, J.N., Gauthier, C., Nebivolol, a vasodilating selective beta-1-blocker, is a beta-3-adrenoceptor agonist in the nonfailing transplanted human heart (2009) J Am Coll Cardiol, 53, pp. 1532-1538 Dessy, C., Saliez, J., Ghisdal, P., Daneau, G., Lobysheva, I.I., Frerart, F., Belge, C., Balligand, J.L., Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol (2005) Circulation, 112, pp. 1198-1205 Iitsuka, H., Tokuno, T., Amada, Y., Matsushima, H., Katashima, M., Sawamoto, T., Takusagawa, S., Miyahara, H., Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: Results from single- and multiple-dose studies (2014) Clin Drug Investig, 34, pp. 27-35 Goldenberg, M.M., Pharmaceutical approval update (2012) Phys Ther, 37, pp. 668-708